I expect them to have us vote on a raised AS this year, expect them to push through another round of gawdy equity bonuses and I fully expect them to tap into and use up the entire $50mm dilution line shortly which will be almost 200 million shares alone(or more depending on the current trajectory). Once you bake it all together with the current equity awards floating around I think north of 2 Billion is certainly possible.
Not so fast, let's not slap an investor of the decade hat on you.
Since you've come here your opinion has fluctuated based upon what day of the week it is. I'm sure you've been trading the stock and that's fine but you've flip-flopped considerably over the years.
Your first week here you were touting approval in 2021 and eventually a 30B market cap, how has that prediction turned out? FWIW from Day 1 I've never pivoted from my opinion, I stated that I hope for cancer patients' sake that the science works but I had zero doubt that LP would dilute investors into oblivion (I always said she's dealing from the bottom of the deck). 2B O/S is definitely in play how many tens of millions do you think will be needed to ramp up to full production if this is ever approved?
Nice to see that you were able to find some entity to give an update on the MHRA application but can we both agree that it shouldn't be this hard for investors to get updates?
and not its prognose for 2021 or 2022 (which looks pretty grim after DCVAX L is approved). Since DCVAX L revenue could grow as big as 3 billion, x15 would mean a MC of 30 billion in the future and at least 50% of that after or just before approval.
Market Data 
Markets 
AI
